Instead, circulating dendritic cells expressing PD-L1 are involved in resistance to Enzalutamide, an anti-androgen drug used for the treatment of castration-resistant PC (CRPC)-patients [96]. This evidence concerns the gene CD274 and pachyonychia congenita.